GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) validation with Jurkat cells by Flow Cytometry (FACS Analysis)

GM R&D department tested the binding ability of GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) to the Jurkat cells by Flow Cytometry. Below is the conclusion:

1.Good binding of GM-528 to Jurkat cells.

2.High concentration (10ug/ml) of GM-528 should be used for CD3 detection.3.The CD3 antibody is derived from L2K. The affinity of L2K is about 35 times lower than OKT

3. (Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3. Cancer Res. 2008)

Figure 1. GeneMedi's GMP-Bios-ab-528 (Pre-Made Solitomab biosimilar) is validated to bind the Jurkat cells by Flow Cytometry (FACS Analysis).